Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines

WATERTOWN, Mass. - July 30, 2023 - PRLog -- Global vaccine development includes a total of 966 vaccine candidates as of January 1, 2023, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.

Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), due to their good safety, stability and ease of manufacture.

The success of COVID-19 mRNA vaccines has laid the foundation for the development of nucleic acid vaccines, including mRNA and DNA vaccines. These vaccines now account for the second largest portion of the overall pipeline, accounting for 18% (173). Due to the flexibility of this class of vaccines in developing vaccines against highly variable pathogens, many vaccine candidates are currently in development, including COVID-19 (95 candidates), influenza (24), and HIV (21).

Viral vector vaccines have also attracted attention in recent years because of their potential to induce strong and long-lasting immune responses, including adenoviruses, retroviruses, lentiviruses, and poxviruses. Currently, there are 133 candidate virus vector vaccines under development, and in particular, adenovirus vectors (82) have been widely used to develop vaccines for diseases such as Ebola, HIV, influenza and COVID-19.

Conjugate vaccines followed with 11%, with 109 vaccine candidates. Conjugate vaccines are typically developed against pathogens such as meningococcus, pneumococcus and Haemophilus influenzae. These vaccines are based on the covalent linkage of immunogenic protein carriers (primarily tetanus toxoids, diphtheria toxoids, or group B meningococcal outer membrane proteins) to capsular polysaccharides or peptides to enhance immunogenicity and stability.

The top three diseases for which vaccines are being developed are all caused by viruses: COVID-19 (246; 25%), influenza (104; 11%) and HIV (84; 9%). In addition to more than 50 vaccines that have received market approval or emergency use authorization for COVID-19, 64 vaccine candidates have entered phase 3 or submitted marketing applications, 47% of which are mRNA vaccines. In the current pipeline, there are at least 14 nasal vaccines in development.

As a professional PEG derivatives supplier, Biopharma PEG is committed to providing following PEG products as ingredients used in COVID-19 vaccines.

mPEG-N,N-Ditetradecylacetamide (ALC-0159) (https://www.biochempeg.com/product/mPEG-N,N-Ditetradecyla...)   CAS No. 1849616-42-7
mPEG-DMG CAS NO. 160743-62-4
mPEG-CH2CH2CH2-NH2
mPEG-OH (https://www.biochempeg.com/product/mPEG-OH.html)  CAS NO.: 9004-74-4
mPEG-CM (mPEG-AA)
mPEG-DSPE CAS NO.: 147867-65-0
mPEG-DPPE CAS NO.: 205494-72-0